

# John E Shively

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6110801/publications.pdf>

Version: 2024-02-01

136  
papers

4,673  
citations

76326

40  
h-index

123424

61  
g-index

137  
all docs

137  
docs citations

137  
times ranked

5135  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tâ€cell surface generation of dual bivalent, bispecific Tâ€cell engaging, RNA duplex crossâ€linked antibodies (dbBiTERs) for reâ€directed tumor cell lysis. <i>Biotechnology Journal</i> , 2022, 17, e2100389.	3.5	2
2	Dual-labeled anti-CEA antibody for near-infrared fluorescence and PET imaging of colorectal cancer. , 2022, , .		0
3	Role of lncRNA LIPE-AS1 in adipogenesis. <i>Adipocyte</i> , 2022, 11, 11-27.	2.8	11
4	Abstract 2732: A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy. <i>Cancer Research</i> , 2022, 82, 2732-2732.	0.9	1
5	Isolation and expansion of murine Î³ T cells from mouse splenocytes. <i>Journal of Immunological Methods</i> , 2022, 508, 113322.	1.4	1
6	Reversal of obesity development in <i>Ceacam1</i> <sup>+/+</sup> male mice by bone marrow transplantation or introduction of the human <i>CEACAM1</i> gene. <i>Obesity</i> , 2022, 30, 1351-1356.	3.0	4
7	Preclinical PET Imaging of NTSR-1-Positive Tumors with <sup>64</sup> Cu- and <sup>68</sup> Ga-DOTA-Neurotensin Analogs and Therapy with an <sup>225</sup> Ac-DOTA-Neurotensin Analog. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 651-661.	1.0	4
8	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. <i>Leukemia</i> , 2021, 35, 189-200.	7.2	56
9	TAG-72â€Targeted Î±-Radionuclide Therapy of Ovarian Cancer Using 225Ac-Labeled DOTAyated-huCC49 Antibody. <i>Journal of Nuclear Medicine</i> , 2021, 62, 55-61.	5.0	11
10	Structural characterization of a dimeric complex between the short cytoplasmic domain of CEACAM1 and the pseudo tetramer of S100A10-Annexin A2 using NMR and molecular dynamics. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2021, 1863, 183451.	2.6	7
11	Comparison of CD38-Targeted Î±- Versus Î²-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model. <i>Journal of Nuclear Medicine</i> , 2021, 62, 795-801.	5.0	18
12	Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. <i>Oncolmunology</i> , 2021, 10, 1899469.	4.6	28
13	Homogeneous Cytochrome 579 Is an Octamer That Reacts Too Slowly With Soluble Iron to Be the Initial Iron Oxidase in the Respiratory Chain of <i>Leptospirillum ferriphilum</i> . <i>Frontiers in Microbiology</i> , 2021, 12, 673066.	3.5	1
14	A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy. <i>Cancers</i> , 2021, 13, 5171.	3.7	7
15	Human CEACAM1-LF regulates lipid storage in HepG2 cells via fatty acid transporter CD36. <i>Journal of Biological Chemistry</i> , 2021, 297, 101311.	3.4	3
16	Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 5300-5311.	5.2	9
17	Phosphorylation of human CEACAM1-LF by PKA and GSK3Î² promotes its interaction with Î²-catenin. <i>Journal of Biological Chemistry</i> , 2021, 297, 101305.	3.4	2
18	CXCR2 specific endocytosis of immunomodulatory peptide LL-37 in human monocytes and formation of LL-37 positive large vesicles in differentiated monoosteophils. <i>Bone Reports</i> , 2020, 12, 100237.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64 <sup>64</sup> labeled daratumumab. <i>Blood Advances</i> , 2020, 4, 5194-5202.	5.2	29
20	Improved targeting of an anti- <sup>67</sup> TAG antibody drug conjugate for the treatment of ovarian cancer. <i>Cancer Medicine</i> , 2020, 9, 4756-4767.	2.8	12
21	Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation. <i>Oncotarget</i> , 2020, 9, 1724052.	4.6	12
22	Antibody Targeted PET Imaging of <sup>64</sup> Cu-DOTA-Anti-CEA PEGylated Lipid Nanodiscs in CEA Positive Tumors. <i>Bioconjugate Chemistry</i> , 2020, 31, 743-753.	3.6	16
23	Generation of dual specific bivalent BiTEs (dbBispecific T-cell engaging antibodies) for cellular immunotherapy. <i>BMC Cancer</i> , 2019, 19, 882.	2.6	12
24	CEACAM1 regulates the IL-6 mediated fever response to LPS through the RP105 receptor in murine monocytes. <i>BMC Immunology</i> , 2019, 20, 7.	2.2	24
25	NMR analysis of free and lipid nanodisc anchored CEACAM1 membrane proximal peptides with Ca <sup>2+</sup> /CaM. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2019, 1861, 787-797.	2.6	5
26	Copper 64 <sup>64</sup> labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. <i>Blood</i> , 2018, 131, 741-745.	1.4	54
27	Interferon regulatory factor 1 and a variant of heterogeneous nuclear ribonucleoprotein L coordinately silence the gene for adhesion protein CEACAM1. <i>Journal of Biological Chemistry</i> , 2018, 293, 9277-9291.	3.4	13
28	Tumor Uptake of <sup>64</sup> Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 38-43.	5.0	63
29	Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2268.	4.8	80
30	Stromal-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local remodeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells. <i>International Journal of Cancer</i> , 2018, 143, 1963-1977.	5.1	18
31	SNPs in inflammatory genes CCL11, CCL4 and MEFV in a fibromyalgia family study. <i>PLoS ONE</i> , 2018, 13, e0198625.	2.5	12
32	PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with <sup>89</sup> Zr-Oxine. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1531-1537.	5.0	111
33	Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen". <i>Blood</i> , 2018, 132, 611-611.	1.4	7
34	<sup>64</sup> cu-DOTA-Anti-CD33 PET-CT Imaging for Acute Myeloid Leukemia and Image-Guided Treatment. <i>Blood</i> , 2018, 132, 2747-2747.	1.4	1
35	PET imaging of <sup>64</sup> Cu-DOTA-scFv-anti-PSMA lipid nanoparticles (LNPs): Enhanced tumor targeting over anti-PSMA scFv or untargeted LNPs. <i>Nuclear Medicine and Biology</i> , 2017, 47, 62-68.	0.6	29
36	Diagnostic PET Imaging of Mammary Microcalcifications Using <sup>64</sup> Cu-DOTA-Alendronate in a Rat Model of Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1373-1379.	5.0	12

#	ARTICLE	IF	CITATIONS
37	Characterization of 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-[Methoxy(polyethylene) Tj ETQq1 1 0.784314rgBT /Overlock 10 T and Molecular Dynamics. <i>Bioconjugate Chemistry</i> , 2017, 28, 1777-1790.	3.6	6
38	Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 80-88.	5.1	65
39	The adaptor SASH1 acts through NOTCH1 and its inhibitor DLK1 in a 3D model of lumenogenesis involving CEACAM1. <i>Experimental Cell Research</i> , 2017, 359, 384-393.	2.6	6
40	Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 247-257.	1.0	10
41	ETS transcription factor ELF5 induces lumen formation in a 3D model of mammary morphogenesis and its expression is inhibited by Jak2 inhibitor TG101348. <i>Experimental Cell Research</i> , 2017, 359, 62-75.	2.6	3
42	CEACAM1 is associated with recurrence after hepatectomy for colorectal liver metastasis. <i>Journal of Surgical Research</i> , 2017, 220, 353-362.	1.6	11
43	Clinical implications of carcinoembryonic antigen distribution in serum exosomal fraction—Measurement by ELISA. <i>PLoS ONE</i> , 2017, 12, e0183337.	2.5	70
44	Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 258-265.	1.0	11
45	Induction of antigen-specific T <sub>H</sub> 9 immunity accompanied by mast cell activation blocks tumor cell engraftment. <i>International Journal of Cancer</i> , 2016, 139, 841-853.	5.1	45
46	miRNA-342 Regulates CEACAM1-induced Lumen Formation in a Three-dimensional Model of Mammary Gland Morphogenesis. <i>Journal of Biological Chemistry</i> , 2016, 291, 16777-16786.	3.4	11
47	Induction of Lumen Formation in a Three-dimensional Model of Mammary Morphogenesis by Transcriptional Regulator ID4. <i>Journal of Biological Chemistry</i> , 2016, 291, 16766-16776.	3.4	6
48	CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 421-430.	2.3	13
49	P4H9-detected molecule expression on spindle-shaped fibroblasts indicates malignant phenotype of colorectal cancer. <i>British Journal of Cancer</i> , 2015, 113, 1454-1459.	6.4	3
50	Radioimmunoimaging of Liver Metastases with PET Using a <sup>64</sup> Cu-Labeled CEA Antibody in Transgenic Mice. <i>PLoS ONE</i> , 2014, 9, e106921.	2.5	16
51	<sup>64</sup> Cu Labeled Sarcophagine Exendin-4 for MicroPET Imaging of Glucagon like Peptide-1 Receptor Expression. <i>Theranostics</i> , 2014, 4, 770-777.	10.0	36
52	Phosphorylation of CEACAM1 Molecule by Calmodulin Kinase IID in a Three-dimensional Model of Mammary Gland Lumen Formation. <i>Journal of Biological Chemistry</i> , 2014, 289, 2934-2945.	3.4	15
53	CEACAM1 Long Cytoplasmic Domain Isoform is Associated with Invasion and Recurrence of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 505-514.	1.5	28
54	Functional Imaging of Human Epidermal Growth Factor Receptor 2—Positive Metastatic Breast Cancer Using <sup>64</sup> Cu-DOTA-Trastuzumab PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 23-29.	5.0	142

#	ARTICLE	IF	CITATIONS
55	Facile Preparation of a Thiol-Reactive <sup>18</sup> F-Labeling Agent and Synthesis of <sup>18</sup> F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1178-1184.	5.0	29
56	Sequence analysis and feeding responses evoked by the large molecular form of gastrin releasing peptide (GRP) in the rat GRP-29. <i>Peptides</i> , 2014, 59, 1-8.	2.4	4
57	IRF-1 regulates alternative mRNA splicing of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in breast epithelial cells generating an immunoreceptor tyrosine-based inhibition motif (ITIM) containing isoform. <i>Molecular Cancer</i> , 2014, 13, 64.	19.2	22
58	CEACAM1 regulates Fas-mediated apoptosis in Jurkat T-cells via its interaction with $\beta$ -catenin. <i>Experimental Cell Research</i> , 2013, 319, 1061-1072.	2.6	23
59	Carcinoembryonic antigen-related cell adhesion molecule 1 negatively regulates granulocyte colony-stimulating factor production by breast tumor-associated macrophages that mediate tumor angiogenesis. <i>International Journal of Cancer</i> , 2013, 133, 394-407.	5.1	15
60	Development and Evaluation of <sup>18</sup> F-TTCO-Cys <sup>40</sup> -Exendin-4: A PET Probe for Imaging Transplanted Islets. <i>Journal of Nuclear Medicine</i> , 2013, 54, 244-251.	5.0	98
61	A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. <i>Protein Engineering, Design and Selection</i> , 2013, 26, 187-193.	2.1	30
62	Role of CEACAM1 and CEACAM20 in an In Vitro Model of Prostate Morphogenesis. <i>PLoS ONE</i> , 2013, 8, e53359.	2.5	15
63	Acceleration of Bone Repair in NOD/SCID Mice by Human Monoosteophils, Novel LL-37-Activated Monocytes. <i>PLoS ONE</i> , 2013, 8, e67649.	2.5	19
64	Discovery of Potential New Gene Variants and Inflammatory Cytokine Associations with Fibromyalgia Syndrome by Whole Exome Sequencing. <i>PLoS ONE</i> , 2013, 8, e65033.	2.5	34
65	CEACAM1 Negatively Regulates IL-1 $\beta$ Production in LPS Activated Neutrophils by Recruiting SHP-1 to a SYK-TLR4-CEACAM1 Complex. <i>PLoS Pathogens</i> , 2012, 8, e1002597.	4.7	62
66	Tumor Angiogenesis Mediated by Myeloid Cells Is Negatively Regulated by CEACAM1. <i>Cancer Research</i> , 2012, 72, 2239-2250.	0.9	30
67	The Short Isoform of the CEACAM1 Receptor in Intestinal T Cells Regulates Mucosal Immunity and Homeostasis via Tfh Cell Induction. <i>Immunity</i> , 2012, 37, 930-946.	14.3	40
68	In Vivo Imaging of Transplanted Islets with <sup>64</sup> Cu-DO3A-VS-Cys <sup>40</sup> -Exendin-4 by Targeting GLP-1 Receptor. <i>Bioconjugate Chemistry</i> , 2011, 22, 1587-1594.	3.6	80
69	Site-Specific Conjugation of Monodispersed DOTA-PEG <sub>n</sub> to a Thiolated Diabody Reveals the Effect of Increasing PEG Size on Kidney Clearance and Tumor Uptake with Improved 64-Copper PET Imaging. <i>Bioconjugate Chemistry</i> , 2011, 22, 709-716.	3.6	38
70	Angiopoietins-1 and -2 play opposing roles in endothelial sprouting of embryoid bodies in 3D culture and their receptor Tie-2 associates with the cell-cell adhesion molecule PECAM1. <i>Experimental Cell Research</i> , 2011, 317, 2171-2182.	2.6	17
71	Re-expression of CEACAM1 long cytoplasmic domain isoform is associated with invasion and migration of colorectal cancer. <i>International Journal of Cancer</i> , 2011, 129, 1351-1361.	5.1	63
72	Mechanistic Control of Carcinoembryonic Antigen-related Cell Adhesion Molecule-1 (CEACAM1) Splice Isoforms by the Heterogeneous Nuclear Ribonuclear Proteins hnRNP L, hnRNP A1, and hnRNP M. <i>Journal of Biological Chemistry</i> , 2011, 286, 16039-16051.	3.4	44

#	ARTICLE	IF	CITATIONS
73	Role of CEACAM1, ECM, and Mesenchymal Stem Cells in an Orthotopic Model of Human Breast Cancer. <i>International Journal of Breast Cancer</i> , 2011, 2011, 1-10.	1.2	10
74	Interaction of Actin with Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 (CEACAM1) Receptor in Liposomes Is Ca <sup>2+</sup> - and Phospholipid-dependent. <i>Journal of Biological Chemistry</i> , 2011, 286, 27528-27536.	3.4	9
75	Erratum of "Role of CEACAM1, ECM, and Mesenchymal Stem Cells in an Orthotopic Model of Human Breast Cancer". <i>International Journal of Breast Cancer</i> , 2011, 2011, 1-2.	1.2	9
76	Role of calpain-9 and PKC- $\zeta$ in the apoptotic mechanism of lumen formation in CEACAM1 transfected breast epithelial cells. <i>Experimental Cell Research</i> , 2010, 316, 638-648.	2.6	24
77	Carcinoembryonic Antigen-Related Cell Adhesion Molecule-1 Regulates Granulopoiesis by Inhibition of Granulocyte Colony-Stimulating Factor Receptor. <i>Immunity</i> , 2010, 33, 620-631.	14.3	55
78	Regulation of CEACAM1 transcription in human breast epithelial cells. <i>BMC Molecular Biology</i> , 2010, 11, 79.	3.0	19
79	Generation of Human CEACAM1 Transgenic Mice and Binding of Neisseria Opa Protein to Their Neutrophils. <i>PLoS ONE</i> , 2010, 5, e10067.	2.5	37
80	Generation of Novel Bone Forming Cells (Monoosteophils) from the Cathelicidin-Derived Peptide LL-37 Treated Monocytes. <i>PLoS ONE</i> , 2010, 5, e13985.	2.5	52
81	Pivotal Advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner. <i>Journal of Leukocyte Biology</i> , 2009, 86, 205-218.	3.3	40
82	Mutational analysis of the cytoplasmic domain of CEACAM1-4L in humanized mammary glands reveals key residues involved in lumen formation: Stimulation by Thr-457 and inhibition by Ser-461. <i>Experimental Cell Research</i> , 2009, 315, 1225-1233.	2.6	13
83	Role of Ceacam1 in VEGF induced vasculogenesis of murine embryonic stem cell-derived embryoid bodies in 3D culture. <i>Experimental Cell Research</i> , 2009, 315, 1668-1682.	2.6	26
84	Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils. <i>European Journal of Immunology</i> , 2009, 39, 3181-3194.	2.9	88
85	Alternative Splicing as a Therapeutic Target for Human Diseases. <i>Methods in Molecular Biology</i> , 2009, 555, 127-144.	0.9	11
86	Altered splicing of CEACAM1 in breast cancer: Identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms. <i>Molecular Cancer</i> , 2008, 7, 46.	19.2	41
87	A Versatile Bifunctional Chelate for Radiolabeling Humanized Anti-CEA Antibody with In-111 and Cu-64 at Either Thiol or Amino Groups: PET Imaging Of CEA-Positive Tumors with Whole Antibodies. <i>Bioconjugate Chemistry</i> , 2008, 19, 89-96.	3.6	47
88	Differential cell fates induced by all-trans retinoic acid-treated HL-60 human leukemia cells. <i>Journal of Leukocyte Biology</i> , 2008, 84, 769-779.	3.3	29
89	Neutrophil secondary necrosis is induced by LL-37 derived from cathelicidin. <i>Journal of Leukocyte Biology</i> , 2008, 84, 780-788.	3.3	59
90	Direct Interaction of Tumor Suppressor CEACAM1 with Beta Catenin: Identification of Key Residues in the Long Cytoplasmic Domain. <i>Experimental Biology and Medicine</i> , 2008, 233, 849-859.	2.4	30

#	ARTICLE	IF	CITATIONS
91	Radioiodinated versus Radiometal-Labeled Anti-CEA Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody Fragments: Optimal Pharmacokinetics for Therapy. <i>Cancer Research</i> , 2007, 67, 718-726.	0.9	86
92	Mutation Analysis of the Short Cytoplasmic Domain of the Cell-Cell Adhesion Molecule CEACAM1 Identifies Residues That Orchestrate Actin Binding and Lumen Formation. <i>Journal of Biological Chemistry</i> , 2007, 282, 5749-5760.	3.4	42
93	<sup>18</sup> F labeling for immuno-PET: where speed and contrast meet. <i>Journal of Nuclear Medicine</i> , 2007, 48, 170-2.	5.0	16
94	A Phase I Trial of <sup>90</sup> Y-DOTA-Anti-CEA Chimeric T84.66 (cT84.66) Radioimmunotherapy in Patients with Metastatic CEA-Producing Malignancies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 88-100.	1.0	44
95	<i>Neisseria gonorrhoeae</i> Kills Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 1 (CD66a)-Expressing Human B Cells and Inhibits Antibody Production. <i>Infection and Immunity</i> , 2005, 73, 4171-4179.	2.2	74
96	The Cell-Cell Adhesion Molecule Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 1 Inhibits IL-2 Production and Proliferation in Human T Cells by Association with Src Homology Protein-1 and Down-Regulates IL-2 Receptor. <i>Journal of Immunology</i> , 2004, 172, 3544-3552.	0.8	61
97	Humanization of the anti-CEA T84.66 antibody based on crystal structure data. <i>Protein Engineering, Design and Selection</i> , 2004, 17, 481-489.	2.1	56
98	CEACAM1 and hyperplastic polyps: new links in the chain of events leading to colon cancer. <i>Oncogene</i> , 2004, 23, 9303-9305.	5.9	10
99	Characterization of recombinant soluble carcinoembryonic antigen cell adhesion molecule 1. <i>Biochemical and Biophysical Research Communications</i> , 2004, 318, 227-233.	2.1	10
100	Cell-Cell Adhesion Molecule CEACAM1 is Expressed in Normal Breast and Milk and Associates with $\beta$ <sup>21</sup> Integrin in a 3D Model of Morphogenesis. <i>Journal of Molecular Histology</i> , 2003, 35, 287-299.	2.2	21
101	CEACAM1, a Cell-Cell Adhesion Molecule, Directly Associates with Annexin II in a Three-dimensional Model of Mammary Morphogenesis. <i>Journal of Biological Chemistry</i> , 2003, 278, 50338-50345.	3.4	47
102	CEACAM1-4S, a cell-cell adhesion molecule, mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 521-526.	7.1	161
103	<sup>124</sup> I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1962-9.	5.0	167
104	Protein Epitopes in Carcinoembryonic Antigen. <i>Tumor Biology</i> , 2002, 23, 249-262.	1.8	29
105	Vinyl Sulfone Bifunctional Derivatives of DOTA Allow Sulfhydryl- or Amino-Directed Coupling to Antibodies. Conjugates Retain Immunoreactivity and Have Similar Biodistributions. <i>Bioconjugate Chemistry</i> , 2002, 13, 110-115.	3.6	26
106	Improved initial yields in C-terminal sequence analysis by thiohydantoin chemistry using purified diphenylphosphoryl isothiocyanate: NMR evidence for a reaction intermediate in the coupling reaction. <i>Analytical Biochemistry</i> , 2002, 307, 202-211.	2.4	3
107	An Improved Method for Conjugating Monoclonal Antibodies with N-Hydroxysulfosuccinimidyl DOTA. <i>Bioconjugate Chemistry</i> , 2001, 12, 320-324.	3.6	102
108	Tumor Targeting of Radiometal Labeled Anti-CEA Recombinant T84.66 Diabody and T84.66 Minibody: Comparison to Radioiodinated Fragments. <i>Bioconjugate Chemistry</i> , 2001, 12, 220-228.	3.6	97

#	ARTICLE	IF	CITATIONS
109	Carcinoembryonic Antigen Cell Adhesion Molecule 1 Directly Associates with Cytoskeleton Proteins Actin and Tropomyosin. <i>Journal of Biological Chemistry</i> , 2001, 276, 47421-47433.	3.4	63
110	Specific binding of glucosaminylmuramyl peptides to histones. <i>FEBS Letters</i> , 1999, 454, 152-156.	2.8	6
111	Maleimidocysteineamido-DOTA Derivatives: A New Reagents for Radiometal Chelate Conjugation to Antibody Sulfhydryl Groups Undergo pH-Dependent Cleavage Reactions. <i>Bioconjugate Chemistry</i> , 1998, 9, 72-86.	3.6	92
112	Role of Interferon Regulatory Factor-1 in the Induction of Biliary Glycoprotein (Cell CAM-1) by Interferon- $\beta$ . <i>Journal of Biological Chemistry</i> , 1996, 271, 28181-28188.	3.4	48
113	A Facile, Water-Soluble Method for Modification of Proteins with DOTA. Use of Elevated Temperature and Optimized pH To Achieve High Specific Activity and High Chelate Stability in Radiolabeled Immunoconjugates. <i>Bioconjugate Chemistry</i> , 1994, 5, 565-576.	3.6	150
114	Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. <i>Cancer</i> , 1994, 74, 1575-1583.	4.1	51
115	Sensitivity and specificity of Gold types 1 to 5 anti-carcinoembryonic antigen monoclonal antibodies: Immunohistologic characterization in colorectal cancer and normal tissues. <i>Human Pathology</i> , 1993, 24, 322-328.	2.0	17
116	Carboxylic acid- $\epsilon$ -modified polyethylene: A novel support for the covalent immobilization of polypeptides for C- $\epsilon$ -terminal sequencing. <i>Protein Science</i> , 1992, 1, 58-67.	7.6	23
117	Automated carboxy- $\epsilon$ -terminal sequence analysis of peptides. <i>Protein Science</i> , 1992, 1, 68-80.	7.6	33
118	Automated carboxy-terminal sequence analysis of peptides and proteins using diphenyl phosphoroisothiocyanatidate. <i>Protein Science</i> , 1992, 1, 1622-1633.	7.6	33
119	Expression of carcinoembryonic antigen and related genes in lung and gastrointestinal cancers. <i>International Journal of Cancer</i> , 1992, 52, 718-725.	5.1	46
120	Transcription of biliary glycoprotein I gene in malignant and non-malignant human liver tissues. <i>International Journal of Cancer</i> , 1990, 45, 875-878.	5.1	26
121	Carboxy-terminal sequencing: formation and hydrolysis of C-terminal peptidylthiohydantoins. <i>Biochemistry</i> , 1990, 29, 3145-3156.	2.5	45
122	Expression of Human Placental Aromatase in <i>Saccharomyces cerevisiae</i> . <i>Molecular Endocrinology</i> , 1989, 3, 1477-1487.	3.7	60
123	Predominant Low-Molecular-Weight Proteins in Isolated Brain Capillaries Are Histones. <i>Journal of Neurochemistry</i> , 1989, 53, 1014-1018.	3.9	2
124	Brain Capillary 46,000 Dalton Protein is Cytoplasmic Actin and is Localized to Endothelial Plasma Membrane. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1989, 9, 675-680.	4.3	34
125	Carcinoembryonic antigen: molecular cloning and expression of CEA-related antigens, and the use of monoclonal antibodies to CEA in tumor imaging and therapy. <i>Fresenius Zeitschrift für Analytische Chemie</i> , 1988, 330, 310-311.	0.8	2
126	Processing of Mammalian Preprogastrin-Releasing Peptide. <i>Annals of the New York Academy of Sciences</i> , 1988, 547, 21-29.	3.8	21



#	ARTICLE	IF	CITATIONS
127	Amyloid Angiopathy of Alzheimer's Disease: Amino Acid Composition and Partial Sequence of a 4,200-Dalton Peptide Isolated from Cortical Microvessels. <i>Journal of Neurochemistry</i> , 1987, 49, 1394-1401.	3.9	70
128	Demonstration of structural differences between the two subunits of human-plasma fibronectin in the carboxy-terminal heparin-binding domain. <i>FEBS Journal</i> , 1987, 162, 403-411.	0.2	22
129	Isolation of a cDNA for adrenodoxin reductase (ferredoxin -NADP+ reductase). Implications for mitochondrial cytochrome P-450 systems. <i>FEBS Journal</i> , 1987, 169, 449-455.	0.2	33
130	Affinity labeling of the active site of pig liver NADH-cytochrome b5 reductase by 5?-p-fluorosulfonylbenzoyl-adenosine. <i>The Protein Journal</i> , 1986, 5, 133-145.	1.1	3
131	Cea-related antigens: Molecular biology and clinical significance. <i>Critical Reviews in Oncology/Hematology</i> , 1985, 2, 355-399.	4.4	229
132	Purification of Somatostatin from Frog Brain: Coisolation with Retinal Somatostatin-Like Immunoreactivity. <i>Journal of Neurochemistry</i> , 1985, 45, 1869-1874.	3.9	21
133	Apparent anomalies in the resolution of cytochrome <i>c</i> -450 isoenzymes by gel electrophoresis. <i>Biochemical Society Transactions</i> , 1984, 12, 62-68.	3.4	10
134	Structure of Somatostatin Isolated from Bovine Retina. <i>Journal of Neurochemistry</i> , 1983, 41, 601-606.	3.9	28
135	Confirmation of the primary structure of thymosin $\beta_4$ by microsequence analysis of limited acid and enzymatic hydrolysis fragments. <i>International Journal of Peptide and Protein Research</i> , 1983, 21, 93-99.	0.1	7
136	Carcinoembryonic Antigen—A Marker of Human Colonic Cancer. <i>ACS Symposium Series</i> , 1978, , 342-356.	0.5	5